Clavamox

DRUG2 trials

Sponsors

Pharmtechnology LLC

Conditions

Bioequivalence

Phase 1

Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

CompletedNCT03616301

Pharmtechnology LLCBioequivalence

Start: 2018-07-28End: 2018-08-13Updated: 2018-10-15

Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

CompletedNCT03702894

Pharmtechnology LLCBioequivalence

Start: 2018-09-21End: 2018-10-08Updated: 2019-05-14